BeiGene sees FY25 revenue $4.9B-$5.3B, consensus $5.09B
TipRanks
May. 7, 2025, 04:20 AM
06:19 EDT BeiGene (ONC) sees FY25 revenue $4.9B-$5.3B, consensus $5.09B
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
Disclaimer & DisclosureReport an Issue
- BeiGene says USPTO invalidates Pharmacyclics’ ‘803 patent
- Reddit initiated, Roku upgraded: Wall Street’s top analyst calls
- BeiGene initiated with an Outperform at RBC Capital
- BeiGene’s Strategic Positioning and Growth Potential: A Buy Recommendation by Reni Benjamin
- BeiGene to discontinue development program for ociperlimab (BGB-A1217)
